André Marc

[André Marc @MarcAndre64]

First resolution for 2025: I am leaving this platform for good.

Find me @bluesky
https://t.co/K5mJ9oDZJn 🦋

[Stefano Luminari, MD @StefanoLuminari]

It was a true honour to be part of this practice changing study #inmind for RR FL. Main messages in addition to better efficacy…fixed duration w/o excess events after tx stop, no added toxicity, excellent TTNT…works in high risk pts, my best choice for 2L FL. #lymsm #ash24

[Jordan Gauthier @drjgauthier]

#ASH24 session acknowledging the legacy of Prof. Éliane Gluckman awarded the Wallace H. Coulter award for a lifetime of achievement in cord blood transplantation.
Room packed with attendees and excitement in anticipation of the Plenary Session!
#womeninmedicine

[ELI @EliLymphoma]

Big success for ELI's 10th Workshop on "Lymphoma of immune privilege sites" held last week in Stresa!

[Ingrid Glimelius @glimelius]

Teaching at #ESMOAcademy, @myESMO in Zurich about #Hodgkin. Great audience.
My take home:
📣 PET CT at dx and after 2 chemo decide treatment
📣 Limit relapse check-up to 2 years, next focus on late effects
📣 Fertility counseling
📣 BrECADD new standard
📣 Nivo-AVD in elderly?

[Blood Journals Portfolio @BloodPortfolio]

O can safely be used in combination with chemotherapy and in maintenance after ASCT as frontline therapy in patients with MCL. https://t.co/tndKk0gxUr #clinicatrialsandobservations #lymphoidneoplasia

[Jordan Gauthier @drjgauthier]

👀

[Côme Bommier @ComeBommier]

Ce 12 juillet, les pilotes de la @PAFofficiel ont laissé leurs alphajets pour venir visiter @HopSaintLouis par le biais de l’association @AssoELLyE.

Un elan du cœur pour les patients atteints de lymphome et ceux qui les soignent 🇫🇷❤️

Cc @APHP @c_thieblemont @FenauxP

[Jonathan Friedberg @DrJFriedberg]

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma | Journal of Clinical Oncology https://t.co/NF1tM1EL6r

[Arina Martynchyk @MartynchykArina]

Surprise-surprise :)

[Toby Eyre @tobyeyre82]

Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma https://t.co/fOsBj9H6DS

[Saheli Sadanand @SaheliSadanand]

📢 Proud to see this important, timely comment by @DrLauraEsserman & @DougYeeMD just published in @NatureMedicine. I 💯 agree: Science & medical groups should stop holding conferences in anti-choice states. Abortion IS healthcare! #WomensRights
Please RT!
https://t.co/88lqXYsDPv

[Kai Rejeski @KRejeski]

DESCAR-T strikes again…

Largest study on transfusion use post CART led by @HouotRoch out today in @BloodAdvances ⤵️

https://t.co/KhHkntn1Mp

Enjoyed writing the associated commentary with @moh7madhomod! Check it out ⤵️

https://t.co/qxgMb1u5VR

@MSKCancerCenter

[Jonathan Friedberg @DrJFriedberg]

Final Analysis of the Ro-CHOP Trial in T-cell lymphoma: In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm. @JCO_ASCO https://t.co/PHrlYophq3

[Luciano J Costa @End_myeloma]

Why some clinical trials cost >$100k per patient in one picture. #mmsm #MedTwitter

[Côme Bommier @ComeBommier]

Célébrez Noël 🎅🏼 en offrant les meilleurs équipements d’activité physique adaptée pour les patients atteints de lymphome!

Car oui, la forme physique optimise les résultats thérapeutiques.💪

Un grand merci pour votre générosité. 🎄🎁

Cc @c_thieblemont @Roberta04704608 @APHP

[Toby Eyre @tobyeyre82]

Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study https://t.co/ydQfPLoNf8

[Michael Wang, MD @michaelwangmd]

It was such an exciting time presenting our data on SYMPATICO trial. It is a milestone achievement for our patients with mantle cell lymphoma in the world!

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Finally, analyzing 310 blood samples from 109 patients we found that #PhasEDSeq #MRD better captures relapse risk than functional imaging by PETCT. 12/15

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature. #lymsm 1/15
https://t.co/FOBvWSu5Je PDF link at bottom of this thread